New treatments and indications to receive a national coverage in Spain

10

Jul 2018

On the 24th April, the Interterritorial Council of the National Health System in Spain made number of decisions about coverage for new services or indications in the National Benefit Catalogue.

During the Interterritorial Council, other important decisions were made. It was also informed about the decision of the Comisión de Prestaciones, Aseguramiento y Financiación on different products to be included in the National Portfolio.

Based on the decisions of the Comisión de Prestaciones, Aseguramiento y Financiación, three new benefits were approved:

  • funding of hearing aids until 26 years old, which was initially until 20 years old;
  • micropigmentation of the nipples as part of the breast reconstruction;
  • monitoring of the glucose using sensors in children, which will allow avoiding needlestick to know their glucose level.

The changes are still due to be formalized in a form of a Royal Decree. After release of the Royal Decree, these benefits must be provided by all Autonomous Communities to the covered population. 

See the full details in Spanish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

24

Feb 2022

On January 18, 2022, the Ministry of Health has awarded the Framework Agreement for the acquisition of 81 linear accelerators included in the High-End Technology Equipment Investment Plan. Furthermore, the National Institute of Health Management (INGESA) has also initiated the processing of the Framework Agreement that will facilitate the acquisition of the equipment in the fields of interventional cardiology, interventional vascular radiology, interventional neurovascular, digital brachytherapy, computed tomography, magnetic resonance imaging, PET-CT, SPECT-CT.

Read more

15

Feb 2022

In January 2022, the Basque Office for Health Technology Assessment (OSTEBA) released an HTA report aiming to assess and compare the efficacy, effectiveness, and safety of the mechanical circulatory support devices most used in the healthcare setting for the treatment and prevention of cardiogenic shock, including Impella® devices, intra-aortic balloon pumps, and extracorporeal membrane oxygenation.

Read more

10

Feb 2022

In January 2022, the Scottish Health Technology Group released a recommendation of the closed-loop systems and the artificial pancreas for type one diabetes mellitus. The limited use of closed-loop systems in routine clinical care makes it difficult to estimate device-related adverse event rates. No evidence was identified for artificial pancreas systems (multi-hormone closed-loop systems) available on the UK market.

Read more